- In patients with newly diagnosed multiple myeloma (NDMM), subcutaneous (SC) administration of bortezomib delivered comparable response rates and survival outcomes vs intravenous (IV) administration, but with a notable reduction in toxicity.
Why this matters
- Limited evidence suggests that SC administration of bortezomib may lead to a reduction in adverse events (AEs) in this setting when compared with IV administration.
- Study to compare the efficacy and safety of bortezomib with IV (n=100) or SC (n=105) administration in 205 patients with NDMM.
- Median patient age, 61 (range, 27-82) years.
- Funding: National Natural Science Foundation of China; Henan Outstanding Person Foundation.
- After cycle 1:
- 31.0% very good partial response or better (≥VGPR) with IV vs 14.3% with SC (P=.004).
- No significant difference in overall response rate (ORR) by administration method for cycles 2-6 (P>.05).
- Median PFS, 37 months with IV vs 45 months with SC (P=.774).
- Median OS, 63 months with IV vs 59 months with SC (P=.667).
- Generally lower incidence of grade ≥3 AEs with SC vs IV.
- 35.2% incidence of overall peripheral neuropathy with SC vs 51.0% with IV (P=.023).
- Retrospective data in Chinese patients.